Cell Biotech Co., Ltd. (KOSDAQ: 049960)

Cell Biotech Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	12,804	7,884	8,458	9,860	9,600	9,422
Short-Term Investments	48,562	56,515	37,671	18,675	23,084	25,388
Trading Asset Securities	16,776	5,933	19,239	29,299	22,203	24,413
Cash & Short-Term Investments	78,143	70,332	65,368	57,834	54,887	59,224
Cash Growth	27.87%	7.59%	13.03%	5.37%	-7.32%	-4.73%
Accounts Receivable	3,667	4,595	4,566	4,664	4,835	4,857
Other Receivables	1,090	943.86	583.11	268.43	283.39	367.36
Receivables	4,970	5,740	5,330	5,216	5,557	5,495
Inventory	4,390	4,122	4,102	3,589	3,503	3,076
Prepaid Expenses	200.97	691.85	500.5	292.5	218.67	233.3
Other Current Assets	158.46	1,044	354.58	587.81	746.72	1,230
Total Current Assets	87,862	81,929	75,655	67,519	64,913	69,258
Property, Plant & Equipment	31,699	32,937	33,638	34,057	36,602	36,065
Long-Term Investments	501.94	501.94	3,786	8,427	2	2
Other Intangible Assets	1,705	1,599	1,793	1,536	1,802	1,702
Long-Term Accounts Receivable	0	0	0	0	0	0
Long-Term Deferred Tax Assets	259.29	182.29	449.3	751.56	1,395	579.45
Other Long-Term Assets	501.83	491.37	517.21	585.15	587.54	697.27
Total Assets	122,530	117,641	115,839	112,877	105,301	108,303
Accounts Payable	634.48	578.39	1,370	1,224	887.65	1,009
Accrued Expenses	1,014	489.15	443.91	470.95	496.32	432.87
Current Portion of Leases	659.76	621.14	600.78	402.89	658.65	413.04
Current Income Taxes Payable	1,058	-	1,038	814.73	-	-
Current Unearned Revenue	28.43	27.03	30.9	50.44	41.52	31.19
Other Current Liabilities	2,643	3,106	3,905	2,802	2,546	2,302
Total Current Liabilities	6,038	4,821	7,389	5,766	4,630	4,189
Long-Term Leases	673.72	934.17	357.79	423.49	686.44	512.08
Other Long-Term Liabilities	-	-	-	0	-	-
Total Liabilities	6,711	5,755	7,747	6,189	5,317	4,701
Common Stock	4,700	4,700	4,700	4,700	4,700	4,700
Additional Paid-In Capital	12,760	12,760	12,760	12,760	12,760	12,760
Retained Earnings	122,435	118,217	114,993	109,894	102,696	103,848
Treasury Stock	-23,978	-23,978	-23,978	-20,258	-20,258	-17,652
Comprensive Income & Other	-99.01	186.4	-382.91	-408.42	86.97	-53.66
Shareholders' Equity	115,818	111,885	108,092	106,687	99,985	103,602
Total Liabilities & Equity	122,530	117,641	115,839	112,877	105,301	108,303
Total Debt	1,333	1,555	958.57	826.38	1,345	925.13
Net Cash (Debt)	76,809	68,777	64,409	57,007	53,542	58,299
Net Cash Growth	27.41%	6.78%	12.98%	6.47%	-8.16%	-6.22%
Net Cash Per Share	11216.64	10049.37	9342.06	8061.43	7547.42	7868.29
Filing Date Shares Outstanding	6.84	6.84	6.84	7.07	7.07	7.23
Total Common Shares Outstanding	6.84	6.84	6.84	7.07	7.09	7.41
Working Capital	81,825	77,108	68,266	61,754	60,283	65,069
Book Value Per Share	16922.86	16348.17	15793.91	15086.68	14094.07	13982.73
Tangible Book Value	114,113	110,286	106,299	105,151	98,183	101,901
Tangible Book Value Per Share	16673.68	16114.53	15531.88	14869.49	13840.05	13753.04
Land	9,696	9,765	9,765	9,765	9,784	8,866
Buildings	12,895	13,063	13,349	13,854	14,389	12,316
Machinery	6,418	7,060	7,228	8,033	9,682	9,481
Construction In Progress	433.35	338.95	993.9	247.26	95	3,348

Source: S&P Capital IQ. Standard template. Financial Sources.